Age-adjusted comorbidity and survival in locally advanced laryngeal cancer

Multidisciplinary Larynx Cancer Working Group

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: The purpose of this study was to quantify the relationship among age, pretreatment comorbidity, and survival outcomes in patients with locally advanced laryngeal cancer. Methods: Baseline comorbidity data were collected and age-adjusted Charlson Comorbidity Index (CCI) was calculated for each case. Kaplan-Meier and Cox proportional hazards modeling were used to determine associations with survival. Results: For 548 patients, with a median age of 59 years (range 31-91 years), 58% were treated with larynx preservation and the rest with total laryngectomy and adjuvant radiotherapy (RT). Two hundred thirty-eight patients (43%) had at least 1 comorbidity each. Cardiovascular diseases were the most common comorbidities (19%). The 5-year overall survival (OS) for patients with CCI ≤3 (n = 442) were superior to CCI >3 (n = 106; 60% vs 41%; P <.0001), although the 5-year disease-specific survival (DSS) rates were not significantly different. The 5-year noncancer CSS was better for age-adjusted CCI ≤3 (88% vs 67%; P <.0001). Conclusion: The age-adjusted CCI is a significant predictor of noncancer CSS and OS for patients with locally advanced laryngeal cancer but is not associated with DSS.

Original languageEnglish (US)
Pages (from-to)2060-2069
Number of pages10
JournalHead and Neck
Volume40
Issue number9
DOIs
StatePublished - Sep 2018

Bibliographical note

Funding Information:
Drs Lai, Mohamed, and Fuller receive funding support from the National Institutes of Health (NIH)/National Institute for Dental and Craniofacial Research (1R01DE025248–01/R56DE025248–01). Dr Fuller is a Sabin Family Foundation Fellow and receives grant and/or salary support from the NIH/ National Cancer Institute (NCI) Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Award (P50CA097007–10) and Paul Calabresi Clinical Oncology Program Award (K12 CA088084–06); the National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QUBBD) Grant (NSF 1557679); the NCI QUBBD (1R01CA225190-01); the NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825-01); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148-01); a General Electric Healthcare/MD Anderson Center for Advanced Biomedical Imaging In-Kind Award; an Elekta AB/MD Anderson Department of Radiation Oncology Seed Grant; the Center for Radiation Oncology Research (CROR) at MD Anderson Cancer Center Seed Grant; and the MD Anderson Institutional Research Grant (IRG) Program. Dr Fuller has received speaker travel funding from Elekta AB. Supported in part by the National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center Support (Core) Grant CA016672 to The University of Texas MD Anderson Cancer Center

Funding Information:
Drs Lai, Mohamed, and Fuller receive funding support from the National Institutes of Health (NIH)/National Institute for Dental and Craniofacial Research (1R01DE025248–01/ R56DE025248–01). Dr Fuller is a Sabin Family Foundation Fellow and receives grant and/or salary support from the NIH/National Cancer Institute (NCI) Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Award (P50CA097007–10) and Paul Calabresi Clinical Oncology Program Award (K12 CA088084–06); the National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QUBBD) Grant (NSF 1557679); the NCI QUBBD (1R01CA225190-01); the NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825-01); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148-01); a General Electric Healthcare/MD Anderson Center for Advanced Biomedical Imaging In-Kind Award; an Elekta AB/MD Anderson Department of Radiation Oncology Seed Grant; the Center for Radiation Oncology Research (CROR) at MD Anderson Cancer Center Seed Grant; and the MD Anderson Institutional Research Grant (IRG) Program. Dr Fuller has received speaker travel funding from Elekta AB. Supported in part by the National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center Support (Core) Grant CA016672 to The University of Texas MD Anderson Cancer Center.

Keywords

  • age
  • comorbidity
  • head and neck cancer
  • larynx cancer
  • radiotherapy
  • survival outcomes

Fingerprint Dive into the research topics of 'Age-adjusted comorbidity and survival in locally advanced laryngeal cancer'. Together they form a unique fingerprint.

Cite this